Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

计划入组 51 人 · 首次发布于 2014 年 10 月 27 日

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

计划入组 597 人 · 首次发布于 2021 年 10 月 13 日

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

计划入组 138 人 · 首次发布于 2015 年 10 月 28 日

Tezacaftor(Symdeko, Trikafta (100 Mg / 50 Mg / 75 Mg; 150 Mg), Symkevi, Kaftrio, Alyftrek)

C₂₆H₂₇F₃N₂O₆

Elexacaftor(Trikafta (100 Mg / 50 Mg / 75 Mg; 150 Mg))

C₂₆H₃₄F₃N₇O₄S

Lumacaftor(Orkambi)

C₂₄H₁₈F₂N₂O₅

Elexacaftor–Tezacaftor–Ivacaftor Shows Promise for Cystic Fibrosis Patients Without F508del CFTR Variant

NICE Recommends Vanzacaftor-Tezacaftor-Deutivacaftor for Cystic Fibrosis Treatment in England

Real-World Data Confirms Trikafta's Long-Term Efficacy as Gold Standard in Cystic Fibrosis Treatment